CTHIn ForceLegislation
National Health (Additional Community Supply Support Payment) Determination 2024
6Amount of ACSS payment
Start here
Get a plain-English read of 6
Turn the raw legal text into a practical explanation grounded in National Health (Additional Community Supply Support Payment) Determination 2024.
#### 6 Amount of ACSS payment
(1) For the purposes of subparagraph 98B(1)(b)(ii) of the Act, the amount of the ACSS payment for each ACSS eligible supply is:
(a) if paragraph (b) of this subsection does not apply—$1.21; or
(b) if subsection (2) or (3) of this section applies to the supply—the sum of:
(i) the amount mentioned in paragraph (a) of this subsection; and
(ii) $4.91.
> Note: An approved pharmacist who wants to receive an ACSS payment must make a claim for the payment under section 99AAA of the Act. Entitlement to the payment is also subject to any applicable conditions determined under section 98C of the Act and the conditions set out in section 99AAAB of the Act.
(2) This subsection applies to an ACSS eligible supply of a pharmaceutical benefit if:
(a) the ACSS eligible supply is made upon an increased maximum quantity prescription directing the supply of:
(i) the benefit; or
(ii) another pharmaceutical benefit that is Schedule equivalent to the benefit; and
(b) the ACSS eligible supply is of the increased maximum quantity of the benefit.
(3) This subsection applies to an ACSS eligible supply of a pharmaceutical benefit if:
(a) the ACSS eligible supply is made to a person in accordance with section 89A of the Act (which deals with supplies of pharmaceutical benefits without a prescription); and
(b) the immediately preceding supply to the person of the benefit, or of another pharmaceutical benefit that is Schedule equivalent to the benefit, was made upon an increased maximum quantity prescription directing the supply of:
(i) the benefit; or
(ii) another pharmaceutical benefit that is Schedule equivalent to the benefit; and
(c) both the ACSS eligible supply, and the immediately preceding supply referred to in paragraph (b) of this subsection, are of the increased maximum quantity of the relevant pharmaceutical benefit.